AGEN1423

AGEN1423 (also known as dalutrafusp alfa) is Agenus's bifunctional fusion protein - an anti-CD73 antibody backbone fused to a TGFβ receptor-based 'trap' domain - that simultaneously blocks CD73, an enzyme tumors use to manufacture immune-suppressing adenosine, and sequesters free TGFβ, a growth factor that turns down T-cell killing and stiffens the tumor stroma. It is being evaluated in a 24-patient investigator-initiated Phase 2 study (NCT05632328) at Beth Israel Deaconess, combining AGEN1423 with botensilimab (Agenus's Fc-enhanced anti-CTLA-4 antibody), with or without standard gemcitabine plus nab-paclitaxel chemotherapy, in advanced pancreatic ductal adenocarcinoma [2]. The combination is a swing for the fences in a cancer that has buried every prior checkpoint-inhibitor combination tested in it, and at Agenus, where cash is acutely limited and the pipeline is increasingly focused on botensilimab combinations in colorectal cancer, a positive readout from this study has outsized strategic value for what is otherwise a back-burner asset.

AGEN1423 is a novel compound, never approved anywhere. The current Phase 2 (NCT05632328) is an investigator-initiated study run by Bruno Bockorny at Beth Israel Deaconess, not a company-sponsored registration trial; that distinction matters because the n=24 dataset will inform but not directly enable approval [2]. Agenus has not disclosed any FDA breakthrough or fast-track designation for AGEN1423 in pancreatic cancer. The compound has prior Phase 1 safety data published as dalutrafusp alfa (Tolcher et al., J Immunother Cancer 2023), where it was tolerated up to 45 mg/kg every two weeks in 21 patients but did not show breakout monotherapy activity across advanced solid tumors [1]. The Phase 2 dose and schedule are not publicly disclosed in detail, but the Phase 1 program established a tolerable upper bound that the combination study can draw from. The PDAC trial is listed as active, not recruiting, which suggests enrollment is complete or near-complete; a data readout is plausible in 2026 but Agenus has not committed to a public timeline. Agenus's financial position is acute: the company reported $9.5M in cash and equivalents as of June 30, 2025, against approximately $22.9M/quarter in operating cash burn (H1 2025 cash used in operations of $45.8M), implying roughly one quarter of standalone runway absent the announced $91M Zydus partnership infusion expected at closing [5][6]. The company has shifted its primary commercial narrative toward botensilimab plus balstilimab in colorectal cancer, where the BOT/BAL combination has shown the most interesting clinical activity [5]. AGEN1423 sits well below that program in priority. Any Phase 2 readout from this trial is a science signal, not a near-term commercial inflection; there is no path from a 24-patient open-label cohort to FDA submission without a much larger randomized study.

Pancreatic tumors are immunologically 'cold' - a thick fibrotic stroma plus active immune suppression keeps T cells out and turns them off when they do get in. Two of the worst offenders are CD73 and TGFβ. CD73 is an enzyme sitting on tumor and stromal cells that converts AMP (adenosine monophosphate) into adenosine; high adenosine in the tumor acts like a chemical sedative on T cells and NK cells, blocking their killing function. TGFβ is a growth factor the tumor secretes that does several bad-for-the-patient things at once: it pushes T cells into an exhausted state, recruits regulatory T cells that further suppress immunity, and reinforces the dense stromal wall that physically excludes immune cells from the tumor. AGEN1423 is engineered as a single fusion molecule with two jobs: an anti-CD73 antibody backbone blocks adenosine production, and a fused TGFβ receptor 'trap' domain sequesters free TGFβ in the local tumor microenvironment [1]. The trap architecture matters because it sponges up the ligand itself rather than blocking a single receptor, theoretically draining the local TGFβ pool more completely. The biological rationale is clean. The validation is weaker. CD73 inhibition has been tested as monotherapy and in combinations across multiple programs - AstraZeneca's oleclumab, Arcus's quemliclustat, and others - and the field has yet to deliver a registrational win. TGFβ trapping has a checkered history; Merck KGaA's bintrafusp alfa, the PD-L1/TGFβ trap with similar architecture, was discontinued in NSCLC (INTR@PID Lung 037) in January 2021 after failing to meet the primary endpoint, and the biliary tract Phase 2/3 (INTR@PID BTC 055) was terminated in August 2021 with no OS benefit over chemotherapy alone and excess bleeding deaths in the experimental arm [3][7]. Combining both mechanisms in one molecule is biologically defensible but does not solve the prior failures.

NCT05632328 is a Phase 2 investigator-initiated trial at Beth Israel Deaconess, sponsored by Dr. Bruno Bockorny rather than directly by Agenus, enrolling roughly 24 patients with advanced pancreatic ductal adenocarcinoma [2]. Patients receive AGEN1423 plus botensilimab - Agenus's Fc-enhanced anti-CTLA-4 designed to better engage myeloid cells - with or without standard gemcitabine and nab-paclitaxel chemotherapy. The two de facto cohorts (±chemo) split the 24 patients roughly in half, leaving approximately 12 patients per arm. At n=12, an observed ORR carries a 95% confidence interval of roughly ±25-28 percentage points (e.g., 4/12 = 33% with a Wilson 95% CI of approximately 14-61%), which makes any single-arm ORR essentially uninterpretable as standalone evidence regardless of the observed value. The primary endpoint is objective response rate, which is a reasonable signal-seeking endpoint for an early combination study but a weak basis for commercial decisions in PDAC, where responses can be transient and overall survival is what payers and oncologists actually care about. The trial is open-label, single-arm per cohort, and small. There is no randomized comparator, so any ORR has to be benchmarked against the registrational MPACT trial (Von Hoff et al., NEJM 2013), which established a 23% ORR for gemcitabine/nab-paclitaxel alone in first-line metastatic PDAC [8]. To claim a real signal against that floor, the AGEN1423 combination would need to clear something like 35% ORR with durable responses, or show a meaningful PFS tail beyond the 5.5-month median PFS chemotherapy alone produced in MPACT. The status is active, not recruiting, which suggests enrollment is complete or near-complete; a readout in 2026 is plausible but not guided. Sample size limits the statistical inference available from this study - it is a proof-of-concept dataset, not a regulatory one, and any positive result would need a much larger randomized confirmatory study before it could change practice.

Our model puts the odds of this drug eventually reaching approval at 6%. That estimate starts from the historical approval rate for Phase 2 drugs in this area - about 13% - then shifts up or down based on ten facts about the trial and its sponsor. Two things help: the trial uses a non-randomized design and light or open-label blinding; two things hurt: the sponsor has a thin or weak approval record and weak or limited earlier-phase results. The remaining factors fall close to average for this stage, so they leave the final estimate near the baseline.

Efficacy risk is the headline. PDAC has buried more checkpoint combinations than any other solid tumor. The biology of pancreatic tumors - sparse T-cell infiltration, dense fibrotic stroma (desmoplasia), and KRAS-driven immune exclusion - is hostile to mechanisms that depend on unleashing existing T cells. KRAS mutations, present in roughly 90% of PDAC, actively shape the immune microenvironment by driving secretion of cytokines that recruit suppressive myeloid cells and exclude effector T cells from the tumor bed. Even if CD73 blockade and TGFβ trapping work as designed at the molecular level, there may not be enough tumor-reactive T cells present in PDAC for them to matter. Safety risk is real but manageable. Anti-CD73 antibodies have shown acceptable safety in prior trials, and dalutrafusp alfa was tolerated up to 45 mg/kg Q2W in the Phase 1 dose-escalation study [1]. TGFβ trapping carries theoretical risks of skin lesions, bleeding, and cardiac effects; bintrafusp alfa had bleeding deaths and skin AEs at meaningful rates, and excess 60-day mortality in the experimental arm contributed to the BTC trial termination [7]. Combining with botensilimab, an Fc-enhanced anti-CTLA-4, raises the immune-related adverse event ceiling: CTLA-4 blockade alone causes colitis, hepatitis, and endocrinopathies, and Agenus's Fc-engineered version is designed for stronger myeloid engagement, which could mean more inflammation. Execution risk centers on Agenus itself. With $9.5M in cash against ~$22.9M/quarter burn as of June 30, 2025 [6], the company has roughly one quarter of standalone runway, and pipeline focus has shifted toward botensilimab combinations in colorectal cancer [5]. The pending $91M Zydus partnership infusion is earmarked for the BOT/BAL Phase 3, not AGEN1423. Commercial risk: even with a positive Phase 2, an n=24 single-arm investigator study cannot register a drug. Agenus would need to fund a randomized Phase 3 in PDAC, which it currently cannot afford alone, and would need a partner to take it forward.

Worth watching, low urgency. The signal that would matter: an ORR readout from NCT05632328 above roughly 35% in the AGEN1423 + botensilimab + chemo cohort (meaningfully above the MPACT 23% floor [8]), with median PFS clearing six months and durable responses. That would put the combination in a different conversation than every prior PDAC immunotherapy attempt and likely force Agenus, or a partner, to commit Phase 3 capital. Anything in the 20-30% range, overlapping with chemotherapy alone, is noise - and at ~12 patients per cohort, the confidence intervals are wide enough that even a 35% point estimate would not be definitive. Check back when Agenus reports next, particularly any 8-K disclosure filing (the SEC form public companies use to announce material events between quarterly reports - readout timing, partnership terms, or trial-update press releases would typically be disclosed via 8-K) [5]. The company's broader story is botensilimab in colorectal cancer, where the BOT/BAL combination has shown the most interesting activity; AGEN1423 is a secondary asset and may not survive internal prioritization if cash gets tighter. The investigator-initiated structure itself is informative: Agenus is letting an academic site run this study on a small budget rather than funding a company-sponsored registration program, which tells you where AGEN1423 sits on the internal priority list. For anyone tracking the CD73/TGFβ mechanism more broadly, the more important readouts to watch are from Arcus Biosciences' quemliclustat and AstraZeneca's oleclumab - those programs have larger studies and earlier readouts that will set the mechanistic ceiling for AGEN1423's odds in PDAC and elsewhere.